NCT04728087 is a NA clinical trial of ACCEL® Absorbable Hemostat Powder in Hemostasis, sponsored by Hemostasis, LLC.

Who is sponsoring NCT04728087?

NCT04728087 is sponsored by Hemostasis, LLC.

What drugs are being tested in NCT04728087?

Interventions in NCT04728087: ACCEL® Absorbable Hemostat Powder, Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01).

What condition does NCT04728087 study?

NCT04728087 studies Hemostasis.

Is NCT04728087 still recruiting?

NCT04728087 is currently status unknown. Last updated 17 July 2024.

Last reviewed 2024-07-17 · How we verify

NCT04728087

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACCEL Absorbable Hemostat

Status unknown NA Last updated 17 July 2024

What this trial tests

NA trial testing ACCEL® Absorbable Hemostat Powder in Hemostasis in 216 participants. Status unknown.

Timeline

26 October 2021

Primary endpoint
30 November 2024

30 January 2025

Quick facts

Lead sponsor	Hemostasis, LLC
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	216
Start date	26 October 2021
Primary completion	30 November 2024
Estimated completion	30 January 2025
Sites	7 locations across United States

Drugs / interventions tested

ACCEL® Absorbable Hemostat Powder
Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01)

Conditions studied

Hemostasis — all drugs for Hemostasis →

Sponsor

Hemostasis, LLC

Who can join

22 and older, any sex, with Hemostasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The ACCEL® Absorbable Hemostat Powder Clinical IDE Trial is designed as a prospective, multi-center, randomized, non-inferiority, controlled pivotal clinical trial to evaluate the safety and efficacy of the ACCEL® Absorbable Hemostat Powder as compared to gelatin sponge, for achieving hemostasis in subjects undergoing cardiovascular, liver, or soft tissue surgery, when control of oozing to moderate bleeding by standard surgical techniques is ineffective and/or impractical.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hemostasis

Currently open trials in the same condition.

NCT06664788 — A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery · NA · recruiting
NCT03430609 — Ovarian Function After Use of Various Hemostatic Techniques During Treatment for Endometrioma · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04728087 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hemostasis, LLC
Last refreshed: 17 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04728087.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing